In fact, pretreatment of cells expressing DC-SIGN with glycan-GNPs exposed to an artificial model of Ebola virus (EBOV-GP) prevented the inhibition of viral gene transduction in a dose dependent manner: dimannoside glycoconjugate shown in Figure 11a has an IC50 value as low as 95 ± 17 pM, making it the most potent glycoconjugate inhibitor against EBOV-GP driven infection reported to date (Figure 11b). This evidence concerns the gene CD209 and infection.